Literature DB >> 9050128

Effect of smoking on neuroleptics in schizophrenia.

R K Salokangas1, S Saarijärvi, T Taiminen, H Lehto, H Niemi, V Ahola, E Syvälahti.   

Abstract

OBJECTIVE: The effect of smoking on daily doses and plasma levels of neuroleptics prescribed for schizophrenic patients was studied.
METHODS: 90 outpatients with schizophrenic disorder (DSM-III-R) who were on a stable regimen of psychotropic medication and showed a stable clinical state were included in a double-blind placebo-controlled trial. Data were collected and blood tests taken at the baseline interview. The plasma levels were obtained for 52 patients.
RESULTS: Daily neuroleptic doses converted to chlorpromazine equivalents correlated significantly (r = 0.436) with the plasma levels of their unmetabolised fractions. The neuroleptic doses increased with age in smokers, while in nonsmokers they decreased. Neither sex, age nor smoking had a significant association with the neuroleptic plasma levels.
CONCLUSIONS: Smoking seems to lead to increased neuroleptic dosages in postmenopausal schizophrenics by increasing hepatic metabolism and renal excretion of the drugs and possibly enhancing dopamine release. It is also possible that older smoking patients form a selected group of heavy smoker and they, therefore, need exceptionally high neuroleptic doses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9050128     DOI: 10.1016/S0920-9964(96)00083-7

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 2.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2013-08-21       Impact factor: 4.530

4.  Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Jincai He; Wei Cheng; Zhiwei Wu; Fu De Yang; Colin N Haile; Hongqiang Sun; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

Review 5.  Selective noradrenaline reuptake inhibitors for schizophrenia.

Authors:  Paul R L Matthews; Jamie Horder; Michael Pearce
Journal:  Cochrane Database Syst Rev       Date:  2018-01-25

6.  The effect of nicotine dependence on psychopathology in patients with schizophrenia.

Authors:  Anne Yee; Nik Nasyrah Bt Nek Mohamed; Aili Hanim Binti Hashim; Huai Seng Loh; Manveen Kaur Harbajan Singh; Chong Guan Ng; S T Jambunathan
Journal:  Biomed Res Int       Date:  2015-04-28       Impact factor: 3.411

7.  A retrospective cohort study of the prevalence of anxiety and agitation in schizophrenic smokers and the unmet needs of smoking cessation programs.

Authors:  Mehgan Hassanzadah; Adib H Bitar; Nile M Khanfar; Fadi T Khasawneh; Kabirullah Lutfy; Gollapudi S Shankar
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

8.  Use of cotinine urinalysis to verify self-reported tobacco use among male psychiatric out-patients.

Authors:  Yatan Pal Singh Balhara; Raka Jain; A Shyam Sundar; Rajesh Sagar
Journal:  Lung India       Date:  2012-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.